Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Imaging procedures, such as positron emission tomography or computed tomography, may help in detecting differences between Hodgkin lymphoma or diffuse large B-cell lymphoma cancer cells. PURPOSE: This clinical trial is studying positron emission tomogaphy and computed tomography in determining differences in Hodgkin lymphoma and diffuse large B-cell lymphoma.

Detailed Description
-----------------
OBJECTIVES: I. Assess the feasibility of detection and quantification of differences in the temporal and spatial distribution of FDG uptake between lesions of HL and DLBCL. OUTLINE: Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans 60 and 180 minutes after FDG administration. After completion of study, patients are followed for 24 hours.

Official Title
-----------------
A Pilot Study to Assess the Feasibility of Detection and Quantification of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using FDG-PET/CT Imaging

Conditions
-----------------
Lymphoma

Intervention / Treatment
-----------------
* Radiation: Fludeoxyglucose F18
* Procedure: Computed Tomography
* Procedure: Positron emission tomography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects with a pathologically-proven diagnosis of classic HL or DLBCL with measurable disease by any imaging technique or physical examination. Exclusion Criteria: Pregnant or nursing, Uncontrolled diabetes mellitus, Active infection, Inability to give informed consent or to comply with all study procedures, Subjects may be excluded at the discretion of the principal investigator or study team members.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Fludeoxyglucose F18 (FDG) PET/CT scans<br>Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans and 180 minutes after FDG administration. | Radiation: Fludeoxyglucose F18<br>* Undergo FDG PET/CT scans<br>* Other names: 18FDG, FDG, Fluorine-18, 2 Fluoro-2-deoxy-D-Glucose, Fludeoxyglucose F18;Procedure: Computed Tomography<br>* Undergo FDG PET/CT scans<br>* Other names: tomography, computed;Procedure: Positron emission tomography<br>* Undergo FDG PET/CT scans<br>* Other names: FDG-PET, PET, PET scan, tomography, emission computed;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage Change in Maximum Lesional FDG Uptake From 60 to 180 Minutes After FDG Administration | Lesional fluorodeoxyglucose (FDG) uptake is measured by standardized uptake value (SUV). The study compared the percentage of change in maximum SUV over 2 hours (first measure was 60 minutes post-administration and second timepoint was 180 minutes post-administration). | 2 hours (between 60 minutes post-administration and 180 minutes post-administration) |